-- RBCキャピタル・マーケッツのアナリストは火曜日のレポートで、クロロックス（CLX）は主に消費の低迷とカテゴリー動向の鈍化により、第3四半期の業績が「軟調」になると予想していると述べた。 アナリストらは、マクロ経済の変動性の高まりを鑑み、同社が通期業績見通しを引き下げるのが適切だろうと指摘した。 クロロックスは木曜日に第3四半期の決算を発表する予定だ。 RBCは「好材料よりも悪材料が多いと予想されるため、今四半期はリスク・リターンがマイナスになると見ている」と述べた。 アナリストらは、クロロックスの株価は改善傾向にあるものの、中東情勢の混乱が第4四半期の売上高と利益の両方に影響を与える可能性が高いと指摘した。 RBCはクロロックス株に対し「セクター・パフォーム」のレーティングと127ドルの目標株価を設定している。
Price: $97.73, Change: $+1.07, Percent Change: +1.11%
3:00 Tuesday vs 3:00 Monday2yr 99-26 vs 100-04; 3.842% vs 3.799%5yr 99-16+ vs 99-21+; 3.981% vs 3.947%10yr 98-06+ vs 98-10+; 4.351% vs 4.335%30yr 97-00 vs 96-31+; 4.941% vs 4.941%2/10 50.633 bps vs 53.307 bps5/30 95.813 bps vs 99.249 bps
Brown & Brown's (BRO) Q1 report shows that the company's organic revenue growth continues to remain under pressure despite better than expected quarterly earnings per share and adjusted margins, UBS said in a note.The company's flat Q1 organic revenue growth was below UBS expectations of a 2% growth and consensus of 1.3%, UBS said on Monday. The metric further excluded $10 million in litigation related lost revenue, which was in-line with expectations, according to UBS.Looking ahead, Brown & Brown expects catastrophe property rates to continue to experience downward pressure in Q2, while economic growth should remain relatively stable, UBS said. The company's capital allocation will have a bias toward buybacks and paying down debt, while remaining active for specialty and smaller deals, UBS added.UBS maintained its neutral rating on the company's stock with an $81 price target.Shares of Brown & Brown were down over 6% in Tuesday trading.Price: $62.07, Change: $-4.06, Percent Change: -6.13%
Incyte (INCY) has an average rating of overweight and mean price target of $109.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $94.83, Change: $-0.89, Percent Change: -0.93%